Asthma
Conditions
Interventions
Group A:formoterol-budesonide
Group B:Healthy subjects, no intervention
Sponsors
West China Hospital, Sichuan University, Chengdu, China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as moderate asthma according to the Global Initiative for Asthma (GINA) 2006: with symptoms daily; exacerbations may affect activity and sleep; nocturnal symptoms more than once a week; daily use of inhaled short-acting ?2-agonist; FEV1 or PEF 60~80% predicted; PEF or FEV1 variability>30%; 2. All asthmatic subjects had never used any steroids within the preceding 180 days; 3. Healthy control subjects were recruited from hospital personnel who answered in the negative to a screening questionnaire for respiratory symptoms, and who had FEV1 values of more than 80% of the predicted value, PC20 methacholine of more than 10 mg/ml, and normal findings on simple chest radiograms; 4. Male and female aged 18 to 70 years old.
Exclusion criteria
Exclusion criteria: 1. patients with chronic bronchitis, or any major comorbid disease that might affect asthma disease activity, such as HIV, metastatic cancer, and congestive heart failue; 2. All subjects were nonsmokers or ex-smokers of at least 2 years with a smoking history of less than 15 pack-years; 3. All subjects had no respiratory tract infections within 2 weeks preceding the two follow-ups.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HRCT scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| induced sputum;lung function; | — |
Countries
China
Contacts
Public ContactKe Wang
Outcome results
None listed